Publicacións nas que colabora con RAFAEL BALAÑA FOUCE (79)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Antileishmanial Effect of 1,5- and 1,8-Substituted Fused Naphthyridines

    Molecules, Vol. 29, Núm. 1

  3. In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania

    Tropical Medicine and Infectious Disease, Vol. 9, Núm. 2

  4. Polyamine Metabolism for Drug Intervention in Trypanosomatids

    Pathogens, Vol. 13, Núm. 1

2023

  1. Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates

    Biomolecules, Vol. 13, Núm. 4

  2. Gel-Free Tools for Quick and Simple Screening of Anti-Topoisomerase 1 Compounds

    Pharmaceuticals, Vol. 16, Núm. 5

  3. Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. Axenic interspecies and intraclonal hybrid formation in Leishmania: Successful crossings between visceral and cutaneous strains

    PLoS neglected tropical diseases, Vol. 16, Núm. 2, pp. e0010170

  2. Characterization of the gene encoding s‐adenosyl‐l‐methionine (Adomet) synthetase in penicillium chrysogenum; role in secondary metabolism and penicillin production

    Microorganisms, Vol. 10, Núm. 1

  3. Design, synthesis and evaluation of novel β-carboline ester analogues as potential anti-leishmanial agents

    Journal of Biomolecular Structure and Dynamics, Vol. 40, Núm. 23, pp. 12592-12607

2021

  1. Bioluminescent Imaging Identifies Thymus, As Overlooked Colonized Organ, in a Chronic Model of Leishmania donovani Mouse Visceral Leishmaniasis

    ACS Infectious Diseases, Vol. 7, Núm. 4, pp. 871-883

  2. Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis

    ACS Infectious Diseases, Vol. 7, Núm. 8, pp. 2390-2401

  3. Hybrid quinolinyl phosphonates as heterocyclic carboxylate isosteres: Synthesis and biological evaluation against topoisomerase 1b (top1b)

    Pharmaceuticals, Vol. 14, Núm. 8

  4. Novel phenanthridine amide analogs as potential anti-leishmanial agents: In vitro and in silico insights

    Bioorganic Chemistry, Vol. 117

  5. Reproduction in trypanosomatids: Past and present

    Biology, Vol. 10, Núm. 6

  6. Simple and fast dna based sensor system for screening of small-molecule compounds targeting eukaryotic topoisomerase 1

    Pharmaceutics, Vol. 13, Núm. 8

2020

  1. Mannose-decorated dendritic polyglycerol nanocarriers drive antiparasitic drugs to leishmania infantum-infected macrophages

    Pharmaceutics, Vol. 12, Núm. 10, pp. 1-21

  2. Screening marine natural products for new drug leads against trypanosomatids and malaria

    Marine Drugs, Vol. 18, Núm. 4

2019

  1. A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery

    PLoS Neglected Tropical Diseases, Vol. 13, Núm. 2

  2. Antileishmanial activity of new hybrid tetrahydroquinoline and quinoline derivatives with phosphorus substituents

    European Journal of Medicinal Chemistry, Vol. 162, pp. 18-31